Mechanisms of transcriptional dysregulation in Huntington's disease

Clinical Neuroscience Research

Volumn 3, Issue 3, 2003, Pages 165-177

  Luthi Carter, Ruth ^a   Cha, Jang Ho J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Expression profiling; Huntingtin; Huntington's disease; Messenger RNA; Polyglutamine disease; Transcription

Indexed keywords

MESSENGER RNA; POLYGLUTAMINE; TRANSCRIPTION FACTOR;

CHROMATIN; DISEASE COURSE; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STEADY STATE; TRANSCRIPTION REGULATION;

EID: 0141828353     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(03)00059-8     Document Type: Article

References (96)

1. Cha J.-H.J. Transcriptional dysregulation in Huntington's disease Trends Neurosci 23 2000 387-392
2. Gerber H.-P. Seipel K. Georgiev O. et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches Science 263 1994 808-811
3. Karlin S. Burge C. Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development Proc Natl Acad Sci USA 93 1996 1560-1565
4. Perutz M.F. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects Curr Opin Struct Biol 6 1996 848-858
5. Imafuku I. Waragai M. Takeuchi S. et al. Polar amino acid-rich sequences bind to polyglutamine tracts Biochem Biophys Res Commun 253 1998 16-20
6. Davies S.W. Turmaine M. Cozens B.A. et al. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease Philos Trans R Soc Lond B Biol Sci 354 1999 981-989
7. Kazantsev A. Preisinger E. Dranovsky A. Goldgaber D. Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells Proc Natl Acad Sci USA 96 1999 11404-11409
8. Preisinger E. Jordan B.M. Kazantsev A. Housman D. Evidence for a recruitment and sequestration mechanism in Huntington's disease Philos Trans R Soc Lond B Biol Sci 354 1999 1029-1034
9. Davies S.W. Turmaine M. Cozens B.A. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537-548
10. DiFiglia M. Sapp E. Chase K.O. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990-1993
11. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19 1997 1147-1150
12. Augood S.J. Faull R.L.M. Love D.R. Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study Neuroscience 72 1996 1023-1036
13. Augood S.J. Faull R.L.M. Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease Ann Neurol 42 1997 215-221
14. Cha J.-H.J. Kosinski C.M. Kerner J.A. et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene Proc Natl Acad Sci USA 95 1998 6480-6485
15. Luthi-Carter R. Strand A. Peters N.L. et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease Hum Mol Genet 9 2000 1259-1271
16. Weeks R.A. Piccini P. Harding A.E. Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease Ann Neurol 40 1996 49-54
17. Mangiarini L. Sathasivam K. Seller M. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493-506
18. Cha J.-H.J. Frey A.S. Alsdorf S.A. et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease Philos Trans R Soc Lond B Biol Sci 354 1999 981-989
19. Turmaine M. Raza A. Mahal A. Mangiarini L. Bates G.P. Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease Proc Natl Acad Sci USA 97 2000 8093-8097
20. Denovan-Wright E.M. Robertson H.A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice Neuroscience 98 2000 705-713
21. DiFiglia M. Sapp E. Chase K. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons Neuron 14 1995 1075-1081
22. Gutekunst C.A. Levey A.I. Heilman C.J. et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies Proc Natl Acad Sci USA 92 1995 8710-8714
23. Wood J.D. MacMillan J.C. Harper P.S. Lowenstein P.R. Jones A.L. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain Hum Mol Genet 5 1996 481-487
24. Velier J. Kim M. Schwarz C. et al. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways Exp Neurol 152 1998 34-40
25. Morton A.J. Edwardson J.M. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease J Neurochem 76 2001 166-172
26. Kusakabe M. Mangiarini L. Laywell E.D. et al. Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene J Comp Neurol 430 2001 485-500
27. Iannicola C. Moreno S. Oliverio S. Nardacci R. Ciofi-Luzzatto A. Piacentini M. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease J Neurochem 75 2000 830-839
28. Bibb J.A. Yan Z. Svenningsson P. et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice Proc Natl Acad Sci USA 97 2000 6809-6814
29. Wyttenbach A. Swartz J. Kita H. et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease Hum Mol Genet 10 2001 1829-1845
30. Harris A.S. Denovan-Wright E.M. Hamilton L.C. Robertson H.A. Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice J Psychiatry Neurosci 26 2001 117-122
31. Deckel A.W. Tang V. Nuttal D. Gary K. Elder R. Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice Brain Res 939 2002 76-86
32. Deckel A.W. Elder R. Fuhrer G. Biphasic developmental changes in Ca2+/calmodulin-dependent proteins in R6/2 Huntington's disease mice NeuroReport 13 2002 707-711
33. Luthi-Carter R. Hanson S.A. Strand A.D. et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain Hum Mol Genet 11 2002 1911-1926
34. Karpuj M.V. Becher M.W. Springer J.E .et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat Med 8 2002 143-149
35. Kita H. Carmichael J. Swartz J. et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling Hum Mol Genet 11 2002 2279-2287
36. Lastres-Becker I. Hansen H.H. Berrendero F. et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease Synapse 44 2002 23-35
37. Luthi-Carter R. Strand A.D. Hanson S.A. et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects Hum Mol Genet 11 2002 1927-1937
38. Chan E.Y.W. Luthi-Carter R. Strand A. et al. Increased huntingtin protein length reduces the severity of polyglutamine-induced gene expression changes in mouse models of huntington disease Hum Mol Genet 11 2002 1939-1951
39. Li S.H. Cheng A.L. Li H. Li X.J. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin J Neurosci 19 1999 5159-5172
40. Wu Z.L. O'Kane T.M. Scott R.W. Savage M.J. Bozyczko-Coyne D. Protein tyrosine phosphatases are up-regulated and participate in cell death induced by polyglutamine expansion J Biol Chem 277 2002 44208-44213
41. Sipione S. Rigamonti D. Valenza M. et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses Hum Mol Genet 11 2002 1953-1965
42. Faber P.W. Barnes G.T. Srinidhi J. Chen J. Gusella J.F. MacDonald M.E. Huntingtin interacts with a family of WW domain proteins Hum Mol Genet 7 1998 1463-1474
43. Boutell J.M. Thomas P. Neal J.W. et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin Hum Mol Genet 8 1999 1647-1655
44. Steffan J.S. Kazantsev A. Spasic-Boskovic O. et al. The Huntington's disease protein interacts with p53 and CBP and represses transcription Proc Natl Acad Sci USA 97 2000 6763-6768
45. Nucifora F.C. Jr. Sasaki M. Peters M.F. et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity Science 291 2001 2423-2428
46. Kegel K.B. Meloni A.R. Yi Y. et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription J Biol Chem 277 2002 7466-7476
47. Dunah A.W. Jeong H. Griffin A. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease Science 296 2002 2238-2243
48. Rega S. Stiewe T. Chang D.I. et al. Identification of the full-length huntingtin-interacting protein p231HBP/HYPB as a DNA-binding factor Mol Cell Neurosci 18 2001 68-79
49. Li S.-H. Cheng A.L. Zhou H. et al. Interaction of Huntington disease protein with transcriptional activator Sp1 Mol Cell Biol 22 2002 1277-1287 [Abstract] [Full Text]
50. Kadonaga J.T. Carner K.R. Masiarz F.R. Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain Cell 51 1987 1079-1090
51. Shimohata T. Nakajima T. Yamada M. et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription Nat Genet 26 2000 29-36
52. Mantamadiotis T. Lemberger T. Bleckmann S.C. et al. Disruption of CREB function in brain leads to neurodegeneration Nat Genet 31 2002 47-54
53. Freedman D.A. Wu L. Levine A.J. Functions of the MDM2 oncoprotein Cell Mol Life Sci 55 1999 96-107
54. Suhr S.T. Senut M.C. Whitelegge J.P. Faull K.F. Cuizon D.B. Gage F.H. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression J Cell Biol 153 2001 283-294
55. Hollenberg A.N. Thyroid hormone receptor isoforms, nuclear corepressors and coactivators: new insights into thyroid hormone action Curr Opin Endocrinol Diabetes 5 1998 314-320
56. Yohrling GJ, Farrell LA, Hollenberg AN, Cha J-HJ. Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Mol Cell Neurosci 2003;23:28-38.
57. McCampbell A. Taylor J.P. Taye A.A. et al. CREB-binding protein sequestration by expanded polyglutamine Hum Mol Genet 9 2000 2197-2202
58. Jiang H. Nucifora F.C. Jr. Ross C.A. DeFranco D.B. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein Hum Mol Genet 12 2003 1-12
59. Jenuwein T. Allis C.D. Translating the histone code Science 293 2001 1074-1080
60. Ueda H. Goto J. Hashida H. et al. Enhanced SUMOylation in polyglutamine diseases Biochem Biophys Res Commun 293 2002 307-313
61. Steffan J.S. Bodai L. Pallos J. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 2001 739-743
62. Hockly E. Richon V.M. Woodman B. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc Natl Acad Sci USA 100 2003 2041-2046
63. Chen H. Lin R.J. Xie W. Wilpitz D. Evans R.M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase Cell 98 1999 675-686
64. Hazeki N. Tsukamoto T. Yazawa I. et al. Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine Biochem Biophys Res Commun 294 2002 429-440
65. Waragai M. Lammers C.H. Takeuchi S. et al. PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival Hum Mol Genet 8 1999 977-987
66. Okazawa H. Sudol M. Rich T. PQBP-1 (Np/PQ): a polyglutamine tract-binding and nuclear inclusion-forming protein Brain Res Bull 56 2001 273-280
67. Okazawa H. Rich T. Chang A. et al. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death Neuron 34 2002 701-713
68. Huang C.C. Faber P.W. Persichetti F. et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins Somat Cell Mol Genet 24 1998 217-233
69. Nakamura K. Jeong S.Y. Uchihara T. et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein Hum Mol Genet 10 2001 1441-1448
70. Kazantsev A. Walker H.A. Slepko N. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila Nat Genet 30 2002 367-376
71. Yu Z.X. Li S.H. Nguyen H.P. Li X.J. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice Hum Mol Genet 11 2002 905-914
72. Zuccato C. Ciammola A. Rigamonti D. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease Science 293 2001 493-498
73. Reisine T.D. Fields J.Z. Stern L.Z. Johnson P.C. Bird E.D. Yamamura H.I. Alterations in dopaminergic receptors in Huntington's disease Life Sci 21 1977 1123-1128
74. Richfield E.K. O'Brien C.F. Eskin T. Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease Neurosci Lett 132 1991 121-126
75. Turjanski N. Weeks R. Dolan R. Harding A.E. Brooks D.J. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study Brain 118 1995 689-696
76. Andrews T.C. Weeks R.A. Turjanski N. et al. Huntington's disease progression. PET and clinical observations Brain 122 1999 2353-2363
77. 2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease Mol Brain Res 102 2002
78. MacGibbon G.A. Hamilton L.C. Crocker S.F. et al. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice J Neurosci Res 67 2002 372-378
79. Ariano M.A. Aronin N. Difiglia M. et al. Striatal neurochemical changes in transgenic models of Huntington's disease J Neurosci Res 68 2002 716-729
80. Varani K. Rigamonti D. Sipione S. et al. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin FASEB J 15 2001 1245-1247
81. Cepeda C. Hurst R.S. Calvert C.R. et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease J Neurosci 23 2003 961-969
82. Reiner A. Albin R.L. Anderson K.D. D'Amato C.J. Penney J.B. Young A.B. Differential loss of striatal projection neurons in Huntington disease Proc Natl Acad Sci USA 85 1988 5733-5737
83. Utal A.K. Stopka A.L. Roy M. Coleman P.D. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease Neuroscience 86 1998 1055-1063
84. Menalled L. Zanjani H. MacKenzie L. et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease Exp Neurol 162 2000 328-342
85. Wellington C. Leavitt B. Hayden M.E.A. Huntington disease: new insights on the role of huntingtin cleavage J Neural Transm Suppl 58 2000
86. McCampbell A. Taye A.A. Whitty L. Penney E. Steffan J.S. Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity Proc Natl Acad Sci USA 98 2001 15179-15184
87. Lastres-Becker I. Berrendero F. Lucas J.J. et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB(1) receptors in the basal ganglia of a transgenic model of Huntington's disease Brain Res 929 2002 236-242
88. Glass M. Dragunow M. Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease Neuroscience 97 2000 505-519
89. Fossale E. Wheeler V.C. Vrbanac V. et al. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice Hum Mol Genet 11 2002 2233-2241
90. Schilling G. Becher M.W. Sharp A.H. et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin Hum Mol Genet 8 1999 397-407
91. Hodgson J.G. Agopyan N. Gutekunst C.A. et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration Neuron 23 1999 181-192
92. Levine M.S. Klapstein G.J. Koppel A. et al. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease J Neurosci Res 58 1999 515-532
93. Holbert S. Denghien I. Kiechle T. et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis Proc Natl Acad Sci USA 98 2001 1811-1816
94. Goldstrohm A.C. Albrecht T.R. Sune C. Bedford M.T. Garcia-Blanco M.A. The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1 Mol Cell Biol 21 2001 7617-7628
95. Takano H. Gusella J.F. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor BMC Neurosci 3 2002 15
96. Truant R. Nucleocytoplasmic transport of huntingtin and Huntington's disease Clin Neurosci Res 3 2003 157-164